Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Slides:

Advertisements

Similar presentations

Mizutomo Azuma 1, Michael M. Shi 2, Christian J. Jacques 2, Carl Barrett 2, Kathleen D. Danenberg 3, Syma Iqbal 1, Anthony El-Khoueiry 1, Dongyun Yang.

Advertisements

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Introduction Materials and Methods Results Conclusions CD133 Polymorphisms are associated with clinical outcome in metastatic colorectal cancer (mCRC)

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in.

Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

An update on biological therapies in colorectal cancer Mount Vernon Cancer Network Sept 05 Mark Harrison.

Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)

Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer Trial Study Regimen No. of Patients Disease-Free Survival (%) Hazard Ratio P-Value Overall.

ARTERIAL THROMBOEMBOLIC EVENTS IN A POOLED ANALYSIS OF 5 RANDOMIZED, CONTROLLED TRIALS OF BEVACIZUMAB WITH CHEMOTHERAPY JR Skillings Genentech, Inc, South.

A Micro RNA Polymorphism (MiRSNP) in 3’UTR of K-ras gene was associated with clinical outcome in mCRC patients treated with either single agent cetuximab.

Mizutomo Azuma 1, Dongyun Yang 2, Marinella Carpanu 3, Ellen Hollywood 3, Michael Lue-Yat 3, Wu Zhang 1, Kathleen D. Danenberg 4, Peter V. Danenberg 5,

Prospective study of EGFR intron 1 CA tandem repeats as predictive factor of benefit from cetuximab and irinotecan Antoniotti C 1, 2, Loupakis F 3, Cremolini.

Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

ICAM-1, GRP-78 and NFkB gene polymorphisms associated with clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB

1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal.

Risk Stratified Analysis Improves Prediction of Treatment Benefit Over Subgroup Analysis: Findings from Intergroup N9741 HK Sanoff, ME Campbell, HC Pitot,

Intratumoral mRNA expression of genes involved in angiogenesis and HIF-1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients.

Best of ASCO – Colorectal & Pancreatic Cancers Best of ASCO Colorectal & Pancreatic Cancers Ali Shamseddine, MD Professor of Medicine Head of Hematology/Oncology.

Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

These slides are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated.

Transcription Factor 7-like 2 (TCF7L2) Polymorphism Was Associated with Worse Survival in Three Independent Cohorts from the USA, Austria, and Japan Rita.

KRAS status and efficacy in the first- line treatment of patients with mCRC treated with FOLFOX with or without cetuximab: The OPUS experience Carsten.

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.

Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,

FOLFOX4 with or without Bevacizumab in Previously Treated Advanced Colorectal Cancer: Results from ECOG-E3200 Lee M Ellis, MD Colorectal Cancer Update.

Introduction Patients and Methods Results Conclusion Pericytes are a key component in the maturation of the VEGF driven tumor angiogenic process 1. Bevacizumab.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Time to Secondary Resistance (TSR) After Interruption of Imatinib: Updated Results of the Prospective French Sarcoma Group Randomized Phase III Trial on.

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Tolerability of fluoropyrimidines differs by region Daniel G. Haller on behalf of: Cassidy J, Clarke S, Cunningham D, Van Cutsem E Hoff P, Rothenberg M,

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.

IntroductionPatient baseline characteristics Conclusion The process of EGFR recycling is important mechanism of resistance of cetuximab in colorectal cancer.

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.

Phase III Study of First-Line XELOX Plus Bevacizumab (BEV) for 6 Cycles Followed by XELOX Plus BEV or Single Agent (s/a) BEV as Maintenance Therapy in.

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience.

Pharmacogenetics of Irinotecan Clinical perspectives: utility of genotyping Mark J. Ratain, MD University of Chicago 11/3/04.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

CCO Independent Conference Coverage

University of Southern California, Norris Comprehensive Cancer Center

VEGF and VEGFR1 Gene expression levels predict tumor recurrence in adjuvant colon cancer Yan Ning1, Georg Lurje1, Kathleen Danenberg2, Janine Cooc2, Dongyun.

USC/Norris Comprehensive Cancer Center

Reviewer: Dr Scott Berry Date posted: June 21, 2007

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

A subgroup analysis of a large multicenter study

Published online September 20, 2017 by JAMA Surgery

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Treated with Neoadjuvant Therapy

KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab Marta Schirripa1, Fotios Loupakis1, Chiara Cremolini1, Dongyun.

Presentation transcript:

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV) Harpreet Singh, Alexandra Pohl, Anthony El-Khoueiry, Georg Lurje, Wu Zhang, Dongyun Yang, Yan Ning, Jabi Shriki, Syma Iqbal, Heinz-Josef Lenz University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA References Recent studies have suggested that germline polymorphisms involved in angiogenesis were associated with clinical outcome in patients treated with the VEGF- inhibitor bevacizumab. (Schneider et al. JCO 2008, Manegold et al ASCO 2008). We tested whether functional polymorphisms involved in genes in angiogenesis- (VEGF, KDR, IL-6, CXCR1 and-2), apoptosis (p53) and cell- proliferation (MMP2,-7 and-9, ICAM)-related pathways in an expanded patient cohort of 79 patients with mCRC, treated with FOLFOX or Xelox and BV predict progression-free survival (PFS) or response (RR). genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG J Clin Oncol 2008;26: Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 2.Manegold P, El-Khoueiry A, Lurje G, Singh H, Yang D, Zhang WC, H; Shriki, J; Pohl, A; Iqbal, S; Lenz, HJ ICAM-1, GRP-78, and NFkB gene polymorphisms and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). In: ASCO annual meeting Chicago, IL, USA: J Clin Oncol patients (47 men, 32 women) with a median age of 56 years (range 29-81) were treated with with either FOLFOX/BV (33 patients) or XELOX/BV (46 patients). Radiologic response: 2/79 pts (3%) CR, 41/77 pts (52%) PR, 32/77 pts (41%) SD and 3/79 pts (4%) DP. At a median follow-up of 32.0 months (range: months), the median time to progression was 10.8 months (95% CI: ), whereas median overall survival hasn’t been reached yet. We found IL-6 G-174C (p=0.025, Fisher’s exact test) and p53 codon 72 (p=0.029, Fisher’s exact test) polymorphisms associated with response to BV -therapy. The multivariate logistic regression of IL6 -174G>C and p53 codon 72 showed a borderline significance for IL6 -174G>C (p=0.065) and a significant assocation with RR for p53 (p=0.023), respectively. Furthermore, there were statistically significant associations between MMP C>T, CXCR G>C and PFS (p=0.023 and p=0.014, respectively, log-rank test). In multivariate analysis, MMP C>T demonstrated to be an independent prognostic factor for PFS (adjusted p=0.002); whereas CXCR G>C showed only borderline significance (adjusted p=0.055). These are the first data to predict clinical outcome in mCRC patients treated with FOLFOX/BV or XELOX/BV. Our data demonstrate that functional polymorphisms in MMP-9 and CXCR-1, leading to alteration of transcription, predict PFS in patients treated with the angiogenesis-inhibitor BV. Furthermore, polymorphisms in IL6 and p53 have demonstrated to predict response to BV-treatment. However, confirmation of these findings in larger, prospective genotype-guided clinical trials is warranted. PFS by MMP C>T PFS by CXCR G>C Whole blood samples were obtained from 79 patients, who received first-line treatment for mCRC with FOLFOX ( or XELOX and BV at University of Southern California medical facilities. All patients signed informed consent; patient information was collected through prospective database and chart review. Statistical endpoints of this study were Progression Free Survival (PFS) and Response Rate (RR). Genomic DNA was extracted from white blood cells using the QiaAmp kit (Qiagen, Valencia, CA). Genotyping was performed using PCR-RFLP technique, direct sequencing and 5’-end [ ϒ - 33 P] labeled PCR-protocols.